Logo image of CADL

CANDEL THERAPEUTICS INC (CADL) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CADL - US1374041093 - Common Stock

5.45 USD
+0.12 (+2.25%)
Last: 12/8/2025, 8:00:02 PM
5.46 USD
+0.01 (+0.18%)
Pre-Market: 12/9/2025, 8:18:32 AM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CADL. CADL was compared to 531 industry peers in the Biotechnology industry. The financial health of CADL is average, but there are quite some concerns on its profitability. CADL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CADL has reported negative net income.
CADL had a negative operating cash flow in the past year.
CADL had negative earnings in each of the past 5 years.
In the past 5 years CADL always reported negative operating cash flow.
CADL Yearly Net Income VS EBIT VS OCF VS FCFCADL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

Looking at the Return On Assets, with a value of -20.89%, CADL is in the better half of the industry, outperforming 74.58% of the companies in the same industry.
Looking at the Return On Equity, with a value of -24.54%, CADL belongs to the top of the industry, outperforming 80.04% of the companies in the same industry.
Industry RankSector Rank
ROA -20.89%
ROE -24.54%
ROIC N/A
ROA(3y)-55.97%
ROA(5y)-50.92%
ROE(3y)-140.08%
ROE(5y)-109.18%
ROIC(3y)N/A
ROIC(5y)N/A
CADL Yearly ROA, ROE, ROICCADL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CADL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CADL Yearly Profit, Operating, Gross MarginsCADL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for CADL has been increased compared to 1 year ago.
The number of shares outstanding for CADL has been increased compared to 5 years ago.
Compared to 1 year ago, CADL has an improved debt to assets ratio.
CADL Yearly Shares OutstandingCADL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
CADL Yearly Total Debt VS Total AssetsCADL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

CADL has an Altman-Z score of 8.77. This indicates that CADL is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 8.77, CADL is doing good in the industry, outperforming 79.47% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that CADL is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.01, CADL is in line with its industry, outperforming 44.07% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 8.77
ROIC/WACCN/A
WACCN/A
CADL Yearly LT Debt VS Equity VS FCFCADL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 7.04 indicates that CADL has no problem at all paying its short term obligations.
The Current ratio of CADL (7.04) is better than 69.87% of its industry peers.
CADL has a Quick Ratio of 7.04. This indicates that CADL is financially healthy and has no problem in meeting its short term obligations.
CADL's Quick ratio of 7.04 is fine compared to the rest of the industry. CADL outperforms 70.43% of its industry peers.
Industry RankSector Rank
Current Ratio 7.04
Quick Ratio 7.04
CADL Yearly Current Assets VS Current LiabilitesCADL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for CADL have decreased strongly by -21.43% in the last year.
The Revenue for CADL has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-21.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CADL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.32% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-2.69%
EPS Next 2Y29.91%
EPS Next 3Y7.89%
EPS Next 5Y13.32%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CADL Yearly Revenue VS EstimatesCADL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
CADL Yearly EPS VS EstimatesCADL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CADL. In the last year negative earnings were reported.
Also next year CADL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CADL Price Earnings VS Forward Price EarningsCADL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CADL Per share dataCADL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.91%
EPS Next 3Y7.89%

More info and screens

0

5. Dividend

5.1 Amount

CADL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CANDEL THERAPEUTICS INC

NASDAQ:CADL (12/8/2025, 8:00:02 PM)

Premarket: 5.46 +0.01 (+0.18%)

5.45

+0.12 (+2.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/bmo
Earnings (Next)03-23 2026-03-23/amc
Inst Owners41.74%
Inst Owner Change-9.11%
Ins Owners15.75%
Ins Owner Change2.33%
Market Cap299.20M
Revenue(TTM)N/A
Net Income(TTM)-22.14M
Analysts82.86
Price Target19 (248.62%)
Short Float %18.56%
Short Ratio10.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)95.29%
Min EPS beat(2)48.1%
Max EPS beat(2)142.48%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.97%
PT rev (3m)-9.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.29%
EPS NY rev (1m)45.91%
EPS NY rev (3m)-17.92%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.32
P/tB 3.32
EV/EBITDA N/A
EPS(TTM)-0.57
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.54
OCFYN/A
SpS0
BVpS1.64
TBVpS1.64
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.89%
ROE -24.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.97%
ROA(5y)-50.92%
ROE(3y)-140.08%
ROE(5y)-109.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.79%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.04
Quick Ratio 7.04
Altman-Z 8.77
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)71.98%
Cap/Depr(5y)525.77%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-2.69%
EPS Next 2Y29.91%
EPS Next 3Y7.89%
EPS Next 5Y13.32%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-2.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-31.49%
EBIT Next 3Y-5.1%
EBIT Next 5Y83.51%
FCF growth 1Y14.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.8%
OCF growth 3YN/A
OCF growth 5YN/A

CANDEL THERAPEUTICS INC / CADL FAQ

Can you provide the ChartMill fundamental rating for CANDEL THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to CADL.


What is the valuation status for CADL stock?

ChartMill assigns a valuation rating of 0 / 10 to CANDEL THERAPEUTICS INC (CADL). This can be considered as Overvalued.


How profitable is CANDEL THERAPEUTICS INC (CADL) stock?

CANDEL THERAPEUTICS INC (CADL) has a profitability rating of 1 / 10.


Can you provide the financial health for CADL stock?

The financial health rating of CANDEL THERAPEUTICS INC (CADL) is 5 / 10.